The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

M. Solèr, J. Matz, R. Townley, R. Buhl, J. O'Brien, H. Fox, J. Thirlwell, N. Gupta, G. Della Cioppa

Research output: Contribution to journalArticle

658 Citations (Scopus)

Abstract

The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma. After a run-in period, 546 allergic asthmatics (aged 12-76 yrs), symptomatic despite inhaled corticosteroids (500-1,200 μg daily of beclomethasone dipropionate), were randomized to receive double-blind either placebo or omalizumab every 2 or 4 weeks (depending on body weight and serum total IgE) subcutaneously for 7 months. A constant beclomethasone dose was maintained during a 16-week stable-steroid phase and progressively reduced to the lowest dose required for asthma control over the following 8 weeks. The latter dose was maintained for the next 4 weeks. Asthma exacerbations represented the primary variable. Compared to the placebo group, the omalizumab group showed 58% fewer exacerbations per patient during the stable-steroid phase (p

Original languageEnglish
Pages (from-to)254-261
Number of pages8
JournalEuropean Respiratory Journal
Volume18
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Immunoglobulin E
Beclomethasone
Asthma
Steroids
Antibodies
Placebos
Adrenal Cortex Hormones
Body Weight
Serum
Omalizumab
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., ... Della Cioppa, G. (2001). The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. European Respiratory Journal, 18(2), 254-261. https://doi.org/10.1183/09031936.01.00092101

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. / Solèr, M.; Matz, J.; Townley, R.; Buhl, R.; O'Brien, J.; Fox, H.; Thirlwell, J.; Gupta, N.; Della Cioppa, G.

In: European Respiratory Journal, Vol. 18, No. 2, 2001, p. 254-261.

Research output: Contribution to journalArticle

Solèr, M, Matz, J, Townley, R, Buhl, R, O'Brien, J, Fox, H, Thirlwell, J, Gupta, N & Della Cioppa, G 2001, 'The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics', European Respiratory Journal, vol. 18, no. 2, pp. 254-261. https://doi.org/10.1183/09031936.01.00092101
Solèr, M. ; Matz, J. ; Townley, R. ; Buhl, R. ; O'Brien, J. ; Fox, H. ; Thirlwell, J. ; Gupta, N. ; Della Cioppa, G. / The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. In: European Respiratory Journal. 2001 ; Vol. 18, No. 2. pp. 254-261.
@article{4f563bc6c0fc48669b6f68dc238fca3c,
title = "The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics",
abstract = "The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma. After a run-in period, 546 allergic asthmatics (aged 12-76 yrs), symptomatic despite inhaled corticosteroids (500-1,200 μg daily of beclomethasone dipropionate), were randomized to receive double-blind either placebo or omalizumab every 2 or 4 weeks (depending on body weight and serum total IgE) subcutaneously for 7 months. A constant beclomethasone dose was maintained during a 16-week stable-steroid phase and progressively reduced to the lowest dose required for asthma control over the following 8 weeks. The latter dose was maintained for the next 4 weeks. Asthma exacerbations represented the primary variable. Compared to the placebo group, the omalizumab group showed 58{\%} fewer exacerbations per patient during the stable-steroid phase (p",
author = "M. Sol{\`e}r and J. Matz and R. Townley and R. Buhl and J. O'Brien and H. Fox and J. Thirlwell and N. Gupta and {Della Cioppa}, G.",
year = "2001",
doi = "10.1183/09031936.01.00092101",
language = "English",
volume = "18",
pages = "254--261",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",

}

TY - JOUR

T1 - The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

AU - Solèr, M.

AU - Matz, J.

AU - Townley, R.

AU - Buhl, R.

AU - O'Brien, J.

AU - Fox, H.

AU - Thirlwell, J.

AU - Gupta, N.

AU - Della Cioppa, G.

PY - 2001

Y1 - 2001

N2 - The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma. After a run-in period, 546 allergic asthmatics (aged 12-76 yrs), symptomatic despite inhaled corticosteroids (500-1,200 μg daily of beclomethasone dipropionate), were randomized to receive double-blind either placebo or omalizumab every 2 or 4 weeks (depending on body weight and serum total IgE) subcutaneously for 7 months. A constant beclomethasone dose was maintained during a 16-week stable-steroid phase and progressively reduced to the lowest dose required for asthma control over the following 8 weeks. The latter dose was maintained for the next 4 weeks. Asthma exacerbations represented the primary variable. Compared to the placebo group, the omalizumab group showed 58% fewer exacerbations per patient during the stable-steroid phase (p

AB - The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma. After a run-in period, 546 allergic asthmatics (aged 12-76 yrs), symptomatic despite inhaled corticosteroids (500-1,200 μg daily of beclomethasone dipropionate), were randomized to receive double-blind either placebo or omalizumab every 2 or 4 weeks (depending on body weight and serum total IgE) subcutaneously for 7 months. A constant beclomethasone dose was maintained during a 16-week stable-steroid phase and progressively reduced to the lowest dose required for asthma control over the following 8 weeks. The latter dose was maintained for the next 4 weeks. Asthma exacerbations represented the primary variable. Compared to the placebo group, the omalizumab group showed 58% fewer exacerbations per patient during the stable-steroid phase (p

UR - http://www.scopus.com/inward/record.url?scp=0034881877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034881877&partnerID=8YFLogxK

U2 - 10.1183/09031936.01.00092101

DO - 10.1183/09031936.01.00092101

M3 - Article

VL - 18

SP - 254

EP - 261

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 2

ER -